BRAF and metastatic neoplasm: The use of sequencing data in clinical practice is still in its infancy, particularly in the setting of CRC where mutations in RAS and BRAF as well as the MMR/MSI status are the biomarkers that are predominantly used when deciding on adjuvant treatment strategies for patients with metastatic disease.